110
Participants
Start Date
May 30, 2023
Primary Completion Date
June 19, 2024
Study Completion Date
June 19, 2024
CVC 150 mg
Administered as one 150-mg tablet by mouth once a day with food.
CVC 300 mg
Administered as two 150-mg tablets by mouth once a day with food.
Placebo for CVC 150 mg
Administered as one 150-mg matching placebo tablets by mouth once a day with food.
Placebo for CVC 300 mg
Administered as two 150-mg matching placebo tablets by mouth once a day with food.
Weill Cornell Chelsea CRS (Site # 7804), New York
Weill Cornell Uptown CRS (Site # 7803), New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site # 31787), Rochester
University of Pittsburgh CRS (Site # 1001), Pittsburgh
Vanderbilt Therapeutics (VT) CRS (Site # 3652), Nashville
Case CRS (Site # 2501), Cleveland
Northwestern University CRS (Site # 2701), Chicago
Houston AIDS Research Team CRS (Site # 31473), Houston
University of California, Los Angeles CARE Center CRS (Site # 601), Los Angeles
Harbor University of California Los Angeles Center CRS (Site # 603), Torrance
UCSD Antiviral Research Center CRS (Site # 701), San Diego
UCSF HIV/AIDS CRS (Site # 801), San Francisco
University of Washington Positive Research CRS (Site # 1401), Seattle
Massachusetts General Hospital CRS (MGH CRS) (Site # 101), Boston
Brigham and Women's Hospital Therapeutics (BWH TCRS) CRS (Site # 107), Boston
Washington University Therapeutics (WT) CRS (Site # 2101), St Louis
Chapel Hill CRS (Site # 3201), Chapel Hill
Cincinnati CRS (Site # 2401), Cincinnati
Ohio State University CRS (Site # 2301), Columbus
Collaborators (1)
AbbVie
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH